🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million infections each year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of rising global incidence, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Data and Global Access

Based on results published in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The study included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in many developing nations.

Clinicians treating patients have shared optimism. The availability of a one-pill regimen such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to lessen the impact of the infection for individuals and to stop the proliferation of untreatable gonorrhoea around the world.